Peter Wostyn
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Peter Wostyn, MD, works in the Department of Psychiatry, Psychiatrisch Centrum Sint-Amandus, Beernem, Belgium[1] and is a co-founder of P&X Medical, a biotech company focused on the treatment of intracranial pressure, cerebrospinal fluid turnover and glymphatic flow in neurodegenerative disorders, with a primary focus on glaucoma.[2]
Notable studies
- 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy[3] - (Abstract)
- 2019, Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction[4]
Talks and interviews
Online presence
See also
Learn more
References
- ↑ "Peter Wostyn". LinkedIn. October 22, 2019. Cite has empty unknown parameter:
|dead-url=(help) - ↑ "Technology - P&X Medical". www.px-medical.be. Retrieved October 22, 2019.
- ↑ Wostyn, Peter; De Deyn, Peter Paul (September 2018). "The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy". Medical Hypotheses. 118: 142–145. doi:10.1016/j.mehy.2018.07.007.
- ↑ Wostyn, Peter (October 4, 2019). "Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction". Medical Hypotheses. 134: 109416. doi:10.1016/j.mehy.2019.109416. ISSN 1532-2777. PMID 31622921.
